Printer Friendly

Toll-Like Receptor Ligand-Induced Liver Injury in D-Galactosamine-Sensitized Mice: Differences between TLR7/8 and TLR9 Ligands, Cytokine Patterns, and Cross-Tolerance Induction by TLR2 Ligand Pretreatment.

1. Introduction

Experimental models of inflammation-mediated organ failure and sepsis have greatly contributed to our understanding of pathophysiology in such clinical challenges. In an attempt to cope with the relative insensitivity of rodents to lipopolysaccharide (LPS), Galanos et al. [1] found that D-galactosamine (D-galN) dramatically sensitizes mice to LPS. LPS/D-galN administration has been widely used as a model for sepsis, based on the knowledge that LPS induces sepsis. Recently, several lines of studies have established that LPS/D-galN challenge shows development of acute hepatic inflammation often called "fulminant hepatitis" [2], with some reports arguing differences between LPS-induced systemic inflammation and the hepatic injury induced by LPS/D-galN [3]. Tumor necrosis factor-[alpha] (TNF-[alpha]) has been shown to be a key mediator in the LPS/D-galN system, causing hepatic apoptosis and subsequent necrosis [4].

D-galN is likely to exert hepatotoxicity by inhibiting the biosynthesis of RNA, proteins, and glycogen in hepatocytes [5]. Besides LPS (ligand for Toll-like receptor 4, TlR4), D-galN-sensitized mice have been shown to exhibit increased sensitivities to the toxic effects of other TLR ligands (TLRLs) including CpG DNA (CpG) (for TLR9) and poly (I:C) (for TLR3) as well as unpurified microbial products [2, 6, 7].

An innate immune response leads to intense long-lasting inflammation and often leads to an adaptive immune response. TLR activation has been utilized for vaccine adjuvants [8], signifying the primary role for TLRs as an enhancer of the immune response. It has been well documented that TLRLs can induce type I interferon (IFN) (e.g., IFN[alpha]/[beta]) and proinflammatory cytokines including IL-1[beta], TNF-[alpha], and IL-6 [8]. Activation of TLRs can also induce T helper 1 ([T.sub.h]1) cell-inducing cytokines (e.g., IL-12), regulatory T ([T.sub.reg]) cell-inducing cytokines (e.g., IL-10), and cytokines which promote the development of [T.sub.h]17 cell such as IL-6, transforming growth factor-[beta] (TGF-[beta]), and IL-23, reflecting essential roles for TLRs in maintaining the balance in T cell response [9].

Apart from induction of adaptive immunity, TLRs have been shown to be involved in broader critical conditions such as ischemia-reperfusion, which may lead to multiple organ failure [10, 11]. Inhibition of TLR4 activity reduced mortality in a mouse model of myocardial infarction and reperfusion injury and reduced inflammatory markers [ 12]. TLR4 is considered to mediate sepsis-induced acute kidney injury by causing cytokine and chemokine release [13]. However, specific cytokines that mediate such effects of TLR activation on organ injuries are not fully understood. In a mouse injury model caused by liver ischemia-reperfusion, it has been shown that endoplasmic reticulum stress in Kupffer cells induces IL-6 production for the conversion of natural Tregs (nTreg) to [T.sub.h]17, which leads to severer liver injury [11].

Another topic in innate immunity that has drawn the interest of researchers is the effects of multiple or sequential TLR stimulations. Some cases of multiple stimulations of TLRs show synergy; however, in many cases of sequential activations of TLRs, an induction of tolerance has been observed [14-16]. In the case of cross-tolerance of TLRLs, after sequential activations of different TLRLs, reduced inflammatory responses are often observed upon the second TLR stimulation by attenuated activation of immune cells involving macrophages. Well-studied examples for tolerance-inducing TLRs involve TLR4 and TLR2. For example, macrophages exposed to TLR2 ligands (TLR2Ls) become hyporesponsive to subsequent stimulation with LPS and vice versa [17]. From a practical perspective, it is of interest whether such tolerance induction by TLR stimulations shows any effects in models of organ injury. It is unknown whether conditions causing intense cell stress such as ischemia-reperfusion or exposure to toxic substances that sensitize cells/tissues/organs exhibit enhanced responses to TLR signaling.

In the present study, an intraperitoneal injection mouse model similar to those used in previous reports was used to address the following specific points. First, to compare different TLRLs including R848 (TLR7/8L) and LTA (TLR2L) in combination with D-galN, we conducted a preliminary set of experiments regarding the induction of hepatic injury. Next, to address the issue of potential influences of endogenous TLR4 ligands, we compared the CpG/D-galN effects between TLR4-deficient and wild-type mice. We think that this is a nontrivial attempt as regulated acetylation and localization of high mobility group box 1 protein (HMGB1), which is known to be a damage-associated molecular pattern (DAMP) and an endogenous TLR4L, has recently been implicated in LPS/D-galN-induced liver failure [18]. Finally, to gain insights into the cytokine patterns and potential cross-tolerance, the effect of LTA pretreatment was examined in CpG/D-galN and R848/D-galN mice. We also discuss our findings that, in non-LTA-pretreated mice, CpG/D-galN and R848/D-galN treatments both caused hepatic injury, however, led to distinct cytokine patterns, distinct strain dependency, and distinct degrees of systemic inflammation.

2. Material and Methods

2.1. Mice. Five-week-old female inbred C3H/HeN (harboring wild-type TLR4 and simply referred to as C3H), C3H/HeJ (TLR4-deficient), and C57BL/6 mice were purchased from Charles River Japan (Kanagawa, Japan) and acclimated for seven days before the experiment. Mice were housed individually under controlled lighting (with light on from 8:00 to 20:00h), temperature (24 [+ or -] 0.5[degrees]C), humidity (50 [+ or -] 10%), and ventilation (~35 complete air exchanges per hour). Food (CRF1; Charles River Japan, Kanagawa, Japan) and water were made available ad libitum.

2.2. Reagents. R848 (imidazoquinoline compound), LTA-SA (lipoteichoic acid from Staphylococcus aureus), and CpG DNA type B 1826 (5-CCATGACGTTCCTGACGTT-3') were purchased from InvivoGen (San Diego, CA, USA). LPS (from Escherichia coli 055: B5), poly (I:C) (polyinosinicpolycytidylic acid sodium salt), and D-galN (D-(+)-galactosamine hydrochloride) were purchased from Sigma (Saint Louis, MO, USA).

2.3. Experimental Protocol. Six- to seven-week-old C3H/HeN (TLR4(+)), C3H/HeJ (TLR4(-)), and C57BL/6 mice were injected intraperitoneally with PBS of 200 [micro]l per mouse or PBS buffer containing each of the TLRLs and 20 mg/mouse D-galN. Blood was collected at 1 and 5 h, and the mice were sacrificed at 10 h after the injection of TLRLs/D-galN. Immediately after sacrifice, serum was prepared and stored at -80[degrees]C until analysis. The serum sample was analyzed for serum alanine aminotransferase (ALT) activity with DRI-CHEM4000 (Fujifilm, Tokyo, Japan) based on the protocol provided by the manufacturer. Serum cytokines (TNF-[alpha], IL-6, IFN-[gamma], IL-10, IL-17A, IL-23, and IL-27) were measured by Bio-Plex assay (VERITAS, Tokyo, Japan). All animal experiments were performed in accordance with protocols approved by the experimental animal committee of Teikyo University.

2.4. Statistical Analysis. Statistical significance among groups was assessed using the Wilcoxon matched paired-rank test. Survival studies were analyzed with the Kaplan-Meier curve and log-rank test. All analyses were performed using JMP version 12 software (SAS Institute Japan Ltd., Tokyo, Japan). Data in graphs are presented as mean [+ or -] SD. P values smaller than 0.05 were considered to be significant.

3. Results and Discussion

3.1. Diverse TLRLs Induce Acute Liver Injury in D-galN-Sensitized Mice. The TLRL/D-galN system has widely been utilized in studies on hepatitis and particularly in evaluating compounds for possible protection from hepatitis. Here, we aimed to complement previous reports in terms of types of TLRLs and strain dependence. Serum ALT levels of the C57BL/6 and C3H mice after intraperitoneal injection of several TLRL/D-galN combinations were measured (Table 1). For all combinations, the dose of D-galN was fixed at 20mg/mouse. Considering the practical limitation of the total number of mice tested, we acknowledge that this is a pilot study on a small scale (n = 3), which should be regarded as a qualitative, not quantitative, trial.

Neither TLRL nor D-galN alone induced an increase in serum ALT levels in both strains (Table 1), in agreement with previous reports [6,19]. On the other hand, in C57BL/6 mice, all of the TLRLs tested (LPS, LTA, R848, poly (I:C), and CpG) in combination with D-galN resulted in development of severe acute liver injury at high doses. In contrast, in C3H mice, the administration of LPS (TLR4L)/D-galN and R848 (TLR7/8L)/D-galN caused as severe lethal hepatic injury as in the C57BL/6 mice; however, for the remaining TLRLs (i.e., LTA (TLR2L), poly (I:C) (TLR3L), and CpG (TLR9L)), administration in combination with D-galN induced only modest degrees of increased serum ALT. Although this small-scale analysis did not allow us to draw any significant conclusions, it raised the possibility that there is strain dependency in sensitivity to LTA, poly (I:C), and CpG in D-galN-sensitized mice.

The results presented in Table 1 confirm previous findings on the toxicities of LPS/D-galN, poly (I:C)/D-galN, and CpG/D-galN [4, 6,19]. Although this was a qualitative analysis, LTA (TLR2L) and R848 (TLR7/8L), which have not previously been well studied in this setting, were shown to induce hepatic injury in D-galN-sensitized mice. To confirm the strain dependency suggested in the above (i.e., sensitivity of C57BL/6 but not C3H mice to ligands including CpG/DgalN and sensitivity of both strains to those including R848/D-galN) and to further address the difference between these TLRLs in the pattern of serum proinflammatory cytokines, we added another set of experiments that compared C57BL/6 and C3H mice as well as CpG and R848 (n = 8). The strain dependency was replicated based on the ALT value after the stimulation for both TLRLs in D-galN-sensitized mice. Indeed, here again, C3H was largely insensitive to CpG/D-galN and sensitive to R848/D-galN, whereas C57BL/6 was sensitive to both (Table 2). Both TNF-[alpha] and IL-6 values showed correlations with the ALT values, in line with the previous finding that TNF-[alpha] is the key cytokine mediating the hepatic toxicity of the TLRLs/D-galN [7]. These data confirm the previous finding that CpG/D-galN treatment causes increases in these cytokines, suggesting key roles for these cytokines in hepatotoxicity [6]. These data also showed that R848/D-galN treatment causes increases in these proinflammatory cytokines, suggesting that these are likely to be key mediators for the hepatotoxicity of R848/D-galN.

Intriguingly, despite the high mortality of the mice treated with R848/D-galN (all eight mice died within 9 h after injection for both strains) relative to the CpG/D-galN-treated mice (only four and none of eight died within 10 h for C57BL/6 and C3H mice, resp.), none of the values of ALT, TNF-[alpha], or IL-6 showed a good correlation with the survival data (Table 2). Another feature of these findings was that the responses to CpG/D-galN, but not to R848/D-galN, showed strain dependency. Overall, these findings suggested that the levels of TNF-[alpha] and IL-6 have good prognostic value for hepatic injury as well as the survival rate for CpG/D-galN-treated mice; however, R848/D-galN-treated mice tended to show high mortality despite relatively modest increases in these cytokine levels.

3.2. TLR4 Is Not Involved in CpG/D-galN-Induced Liver Injury. In the above shown was the ability of various TLRLs combined with D-galN to induce liver injury (Tables 1 and 2); however, to the best of our knowledge, no report has formally ruled out the possibility that inflammation is amplified by endogenous ligands for TLR4 including DAMPs in mice treated with TLRLs/D-galN. This is important, as acetylation and localization of HMGB1, a DAMP and an endogenous TLR4 ligand, have recently been shown to undergo changes in LPS/D-galN-induced liver failure [19]. CpG/D-galN can give rise to HMGB1 and heat shock proteins, both being endogenous DAMPs that activate TLR4 [21]. Given these findings, we compared C3H/HeJ (TLR4 deficient) strain and C3H/HeN strain that harbors wild-type TLR4 (TLR4(+)) and the effects of CpG/D-galN treatment (n = 7). The C3H/HeJ (TLR4(-)) mice exhibited a similar degree of liver injury as in C3H/HeN (TLR4(+)) mice at 10 h after the injection (Figure 1). On histological examination, for both strains, the CpG/D-galN-treated mice, but not PBS-injected mice, showed numerous inflammatory foci in the pericentral area with signs of inflammatory liver damage, based on observations of hemorrhage, infiltration of lymphocytes, and scattered eosinophilic degenerative damages of liver cells, which were in good agreement with the similar analysis by Yi et al. [6]. The average of the serum ALT levels in the CpG/D-galN-treated TLR4(+) mice (267.7 IU/l) was not different from that in TLR4(-) mice (258.4 IU/l). Therefore, although we did not test for other TLRLs, these results suggest that the possible confounding effects of endogenous TLR4Ls on TLR9L/D-galN-induced hepatic injury are negligible. The results also rule out a substantial effect of translocation of components of commensal bacteria into the circulation, which could provide LPS.

3.3. LTA Pretreatment Protects Mice from Lethal Liver Injury by CpG/D-galN as well as by R848/D-galN, Whereas These Combinations Differ in Liver versus Systemic Toxicity. Experiments with sequential stimulations have shown that pretreatment with a TLRL can lead to priming (enhancement) or attenuation of effects of the secondary TLR challenge. In particular, LTA (TLR2L) can induce cross-tolerance against a second challenge with LPS [17, 22, 23]. To examine the effects of a TLR2L pretreatment on the liver injury caused by TLRL/D-galN, we administered CpG/D-galN to C57BL/6 mice without or after LTA pretreatment. Without LTA pretreatment (200 [micro]g/mouse), four of seven mice died within 9 h after the CpG/D-galN challenge (Figure 2(a)), which is consistent with the above results. Mortality was significantly reduced in LTA-pretreated mice (Figure 2(a)). When R848/D-galN was used for the second injection, a similar improvement in survival was observed (Figure 2(b)). When C3H instead of C57BL/6 mice were used, a similar improvement in the survival rate was observed in the mice with the LTA pretreatment prior to the R848/D-galN administration (Figure 2(c)). These findings indicate that LTA pretreatment can induce cross-tolerance against the second challenge with either CpG/D-galN or R848/D-galN.

Interestingly, during the experiments without LTA pretreatment, it was observed that all R848/D-galN mice exhibited severe signs of illness (immobility, rough fur, massive blood coagulation, gastrointestinal bleeding, and decrease in body temperature) whereas CpG/D-galN mice did not show any of these symptoms. Moreover, all of the R848/D-galN mice died 6-9 h after the challenge whereas four out of eight CpG/GalN mice survived at 10 h. Analysis of several organs/tissues of the dead R848/GalN mice showed features consistent with multiple organ failure, whereas none of the CpG/D-galN mice showed these symptoms (data not shown).

To gain further insight into the difference between the two TLRLs (CpG and R848) and the effect of LTA pretreatment on the toxicity of these TLRL/D-galN treatments, serum cytokine levels were measured using C57BL/6 mice. The cytokines measured here more or less focused on those associated with Th17 cells (IL-17A, IL-23, and IL-27) based on recent general interest in a Th17 in ischemic-reperfusion and sepsis models [11] as well as in an LPS/D-galN hepatic injury model [24].

Without LTA pretreatment, the two sets of mice (CpG/D-galN and R848/D-galN) showed similar cytokine patterns although it was difficult to draw conclusive differences between the R848 and CpG in our experimental setting (Table 3). One common feature was the induction of IL-6 and TNF-[alpha]. Contrary to our anticipation, the cytokines important for Th17 (IL-17A, IL-23, and IL-27) did not exhibit appreciable changes for both combinations of TLRL/D-galN. Another intriguing feature was relatively high IL-10 levels in the CpG/D-galN-treated mice compared to that in the R848/D-galN-treated mice (Table 3).

Conversely, the CpG/D-galN-treated mice exhibited clear suppression of IL-6 and TNF-[alpha] inductions after LTA pretreatment. Intriguingly, the R848/D-galN-treated mice did not exhibit clear suppression of IL-6 and TNF-[alpha] inductions by LTA pretreatment. For both CpG/D-galN and R848/D-galN, LTA-induced tolerance (Figure 2) was not accompanied by an increase in IL-10 levels, which was rather shown to decrease (Table 3). Although the decrease in IL-10 levels and increases in IL-17A, IL-23, and IL-27 levels were notable (Table 3), these observations need validation through further analyses owing to the limited sample size of this study.

Broadly, the suppression by LTA pretreatment was more evident for the case with the CpG/D-galN-treated mice. For example, IL-6 and TNF-[alpha] levels were reduced by LTA pretreatment. IFN-[gamma] was also suppressed. Intriguingly, LTA pretreatment showed no or little suppression in R848/DgalN mice; for any of TNF-[alpha], IL-6, and IFN-[gamma], there was no reduction relative to the mice without LTA pretreatment. These results demonstrate a discrepancy between the mortality data and cytokine data; although the LTA pretreatment improved the mortality for both combinations of CpG/D-galN and R848/D-galN, the tolerance-inducing effect of the LTA pretreatment on the levels of serum cytokines was clear for CpG/D-galN but not for R848/D-galN.

4. Concluding Discussion

The TLR/D-galN system has been widely used as a model of sepsis and hepatitis, and in particular, for the evaluation of potential drugs that might protect the liver from failure. This study aimed to expand on previous studies on this system in terms of types of TLRL, effects on production of cytokines, and effect of cross-tolerance induction by TLR2L pretreatment. The present results showed that besides LPS, poly (I:C), and CpG, which have been studied by several authors, LTA and R848 can also induce hepatic injury in D-galN-sensitized mice. For CpG/D-galN-treated mice, there was no appreciable level of involvement of endogenous TLR4Ls. We further found that LTA pretreatment can induce cross-tolerance and improve the survival rate against secondary treatment with either CpG/D-galN or R848/D-galN. Despite the finding that hepatic injury by both combinations was suppressed by LTA pretreatment, these combinations exhibited notable differences. Without LTA pretreatment, R848/D-galN showed a greater ability to induce systemic illness compared to CpG/D-galN. Furthermore, the former combination induced increased production of TNF-[alpha], IL-6, and IFN-[gamma], and intriguingly these increases were not suppressed by LTA pretreatment.

In the tolerance induced by the LTA pretreatment, this pretreatment more efficiently improved the survival of CpG/D-galN-treated mice compared to R848/D-galN-treated mice (Figure 2). It was further noted that CpG/D-galN generally showed benign characteristics in that it did not induce systemic organ failure as R848/D-galN did in our setting. TLR9 appeared to be more liver specific, while TLR7/8 caused more systemic damage although hepatic injury was present. Although further comparison is beyond the scope of this study, the differential effects between these TLRLs may be discussed from a perspective on the relevance of the TLRL/DgalN system to sepsis or systemic inflammation. Although the original proposal that the LPS/D-galN system, similar to high-dose LPS treatment, could be considered as a septic model was questioned by several authors who showed that severe apoptotic liver injury was induced by LPS/D-galN [3] and poly (I:C)/D-galN [7], our findings raised a possibility that relatively uncharacterized TLRL/D-galN combinations may show more features of systemic inflammation than the LPS/D-galN system.

It is most likely that our LTA pretreatment elicited many negative regulatory mechanisms that have been elucidated in many studies, causing the tolerance against the second challenges in our setting. LPS tolerance has been extensively studied, but TLR2-induced tolerance has been shown to be important in some settings. Analyses by Turner et al. showed that Brugia malayi female worm- (BMFE-) mediated cross-tolerance to various TLR stimulations is dependent on TLR2 and MyD88 but not on TLR4 [25]. In splenic dendritic cells of zymosan- (TLR2 and dectin-1 agonist) treated mice, TLR2 stimulation mediates the inductions of retinaldehyde dehydrogenase type 2 (Raldh2) and IL-10 expression and stimulates [Foxp3.sup.+] [T.sub.reg] cells induction, suggesting a generally high propensity for tolerance induction after TLR2 signaling [26].

In the studies of TLR-mediated tolerance, a number of negative regulatory controllers have been proposed [27]. Distinct mechanisms are likely to be employed between TLR2- and 4-induced tolerance. For example, in the case of IL-1R-associated kinase (IRAK) that directly interact with MyD88, LTA-induced tolerance does not involve IRAK degradation, unlike the LPS-induced tolerance [28]. Nonetheless, in peptidoglycan- (PGN and TLR2 agonist) induced tolerant cells, IRAK1 kinase activity was inhibited and Nakayama et al. further showed that IRAK-M, a negative regulator of TLR signaling, is induced, likely inhibiting the IRAK1 recruitment to TLR/MyD88 complexes. For another example, kinase activity of IRAK4 is not required for the induction of LPS tolerance but contributes significantly to TLR2-elicited homo- and cross-tolerance [29].

On the other hand, many regulators are likely to be shared by TLR2 and other TLRs in tolerance induction. Using SOCS- (suppressor of cytokine signaling-) 1-deficient macrophages, Nakagawa et al. showed that SOCS-1 is necessary for tolerance to LPS induced by LPS, CpG DNA, or MALP-2 (TLR2/6 agonist) [30]. SOCS-1 exerts its negative regulation through enhancing ubiquitination of several molecules including Mal, which has been shown to be an adaptor protein relatively specific to TLR2 and TLR4 signaling. Upon stimulation of these TLRs, Mal becomes phosphorylated and then recognized by SOCS-1 that causes ubiquitination and degradation [31]. In the case of Tollip that ubiquitinates TLRs and also binds to IRAK1 (thus blocking IRAK4 recruitment), Tollip mRNA upregulation occurs by both LPS and LTA treatment in intestinal epithelial cells [32]. The ubiquitin-modifying enzyme A20 (also referred to as TNF[alpha]-induced protein 3) is induced by stimulations by multiple TLR ligands (TLR2, 3, 4, and 9) and has been implicated for terminations of TLR responses [33]. For the kinases MSK1 and MSK2 that are phosphorylated by p38 MAPK and Erk and exert many negative feedback mechanisms in TLR signaling including IL-10 gene upregulation, LTA and CpG DNA as well as LPS have been shown to trigger activation of their kinase activities [34] For CD200, a cellsurface glycoprotein whose binding to CD200R triggers diverse immune inhibitory mechanisms, a range of TLR agonists such as LPS, PGN, poly (I:C), and CpG DNA can induce CD200 mRNA in macrophages in a c-Rel-dependent manner [35]. Almeida et al. showed a requisite role for TLR2 in Mycobacterium bovis Bacillus Calmette-Guerin- (BCG-) mediated upregulation of peroxisome proliferator-activated receptor [gamma] (PPAR[gamma]) in macrophages [36]. Besides its roles in lipid metabolism, PPARy exerts an anti-inflammatory response in murine and human macrophages, mainly through suppressing activities of transcriptional factors including AP-1, STAT-1, and NF-[kappa]B [37].

MicroRNAs have also been shown to be important in TLR2-induced tolerance. miR-146a has been shown to suppress expression of TNF receptor-activated factor 6 (TRAF6) and IRAK1. Besides LPS-induced tolerance [38], bacterial lipoprotein (TLR2 agonist) treatment-induced tolerance has been shown to upregulate the expression of miR-146a in human THP-1 promonocytic cells [39]. In the case of miR155, the ligands for TLR2, 3, 4, and 9 have been shown to induce expression in macrophages [40]. miR-155 is considered to fine-tune TLR signaling as it targets not only MyD88, TAB2, and IKK[epsilon] but also negative regulators involving SHP-1 and SOCS-1 [41]. Nahid et al. also showed that PGN stimulation caused rapid upregulation of miR-132 and miR-212 THP-1 monocytes and primary macrophages thereby downregulating IRAK4 and that this induction was induction relative to LPS-induced miR-146a induction [42]. It is plausible that many negative regulators including those not considered above are jointly playing important roles in the tolerance we observed in this study. The procedure used in the study may be useful for quick assessments of systemic effects of homo- and cross-tolerance induction by TLR stimulations.

Currently, we can only provide speculative discussions; however, the difference between CpG and R848 shown in Table 3 could be related to the finding that IL-10 levels were high after CpG/D-galN treatment relative to that after R848/D-galN treatment (Table 3). This difference between CpG and R848 may be related to the previous findings on these TLRLs that showed that CpG stimulation with CpG induced high levels of IL-10 production from macrophages [43]. The authors also showed that endogenous IL-10 suppresses IL-12p70 expression induced by CpG, suggesting that CpG signaling has intrinsic mechanisms for feedback that limit the degree of inflammation. It is also plausible that the observed difference between CpG and R848 may be partly caused by differential expression patterns of TLRs. TLR7/8 is not expressed at significant levels in the intestinal epithelium, while TLR9 is abundant [44]. Such differential expressions of TLRLs could contribute to the differential effects shown above. It should also be considered that in combination with TLR2 activation, the activation of either of TLR2, 4, or 9 is suppressed [45], while to our knowledge, there has been no such report on TLR7/8.

Incidentally, our analyses showed strain dependency. To our knowledge, between-strain differences in responses to TLRLs have not been well studied, especially for C3H mice. Yet, Liu et al. [46] showed that TLR9 mRNA levels were much higher in dendritic cells (DC) from naive C57BL/6 mice than in those from BALB/c mice. The expression levels of mRNAs for TLR2, 4, 5, and 6 were low in C57BL/6 DCs from the spleen. Although we have not examined C3H mice in this respect, this pattern of mRNAs appears consistent with our findings that showed high sensitivity of C57BL/6 mice to CpG. As another well-studied example, genetic background has also been shown to be important in the Th1/Th2 balance and septic response in mice [47, 48]. C57BL/6 and BALB/c mice are regarded as Th1- and Th2-dominant mouse strains, respectively [49]. Macrophages from BALB/c mice exhibit a limited IFN-[gamma]-producing activity relative to those from C57BL/6 mice [50, 51]. TNF-]alpha] and IL-12 productions upon TLR2L and TLR4L stimulation in C57BL/6 mouse macrophages were more pronounced than in macrophages of BALB/c mice [52]. Possibly because of this difference, BALB/c mice were more vulnerable to CLP-induced lethality than C57BL/6 mice. Although to our knowledge, C57BL/6 and C3H mice have not been compared in detail, our findings indicated differences in terms of mortality and efficacy of tolerance induction, suggesting the presence of unrecognized genetic influences in several other processes involving TLR functions in vivo.

In summary, the present study showed that in addition to LPS and poly (I:C) and CpG, LTA and R848 can induce hepatic injury in D-galN-sensitized mice. Further, we confirmed that CpG/D-galN is not influenced by endogenous ligands for TLR4. Finally, we showed that CpG and R848 treatments exhibit distinct effects; both showed hepatic injury but distinct degrees of systemic organ failure. The tolerance induction by LTA pretreatment was evident for both TLRLs but clearer for CpG. These findings highlight the differences among TLRs. Our results also demonstrated the presence of strain dependency in both systemic effects and cytokine patterns. Nonetheless, the scale of our analysis was limited, and therefore further experiments will be necessary for a better understanding regarding these issues.

https://doi.org/10.1155/2017/9653793

Conflicts of Interest

The author declares that there is no conflict of interest regarding the publication of this paper.

Acknowledgments

The author thanks Ayuka Kobayashi, Masanobu Hinata, and Mutsuki Kobayashi for their contributions to an early phase of this project.

References

[1] C. Galanos, M. A. Freudenberg, and W. Reutter, "Galactosamine-induced sensitization to the lethal effects of endotoxin," Proceedings of the National Academy of Sciences of the United States of America, vol. 76, no. 11, pp. 5939-5943, 1979.

[2] W. Jiang, R. Sun, H. Wei, and Z. Tian, "Toll-like receptor 3 ligand attenuates LPS-induced liver injury by downregulation of toll-like receptor 4 expression on macrophages," Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 47, pp. 17077-17082, 2005.

[3] A. Mignon, N. Rouquet, M. Fabre et al., "LPS challenge in D-galactosamine-sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock," American Journal of Respiratory and Critical Care Medicine, vol. 159, no. 4, Part 1, pp. 1308-1315, 1999.

[4] M. Nowak, G. C. Gaines, J. Rosenberg et al., "LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-[alpha] and the TNF-p55 receptor," American Journal of Physiology - Regulatory, Integrative and Comparative Physiology, vol. 278, no. 5, pp. 1202-1209, 2000.

[5] R. F. Stachlewitz, V. Seabra, B. Brandford et al., "Glycine and uridine prevent D-galactosamine hepatotoxicity in the rat: role of Kupffer cells," Hepatology, vol. 29, pp. 737-745, 1999.

[6] A. K. Yi, H. Yoon, J. E. Park, B. S. Kim, H. J. Kim, and A. Martinez-Hernandez, "CpG DNA-mediated induction of acute liver injury in D-galactosamine-sensitized mice: the mitochondrial apoptotic pathway-dependent death of hepatocytes," Journal Biological Chemistry, vol. 281, no. 21, pp. 15001-15012, 2006.

[7] L. Dejager and C. Libert, "Tumor necrosis factor alpha mediates the lethal hepatotoxic effects of poly(I:C) in D-galactosamine-sensitized mice," Cytokine, vol. 42, no. 1, pp. 55-61, 2008.

[8] A. Dunne, N. A. Marshall, and K. H. Mills, "TLR based therapeutics," Current Opinion in Pharmacology, vol. 11, no. 4, pp. 404-411,2011.

[9] M. Teixeira-Coelho, A. Cruz, J. Carmona et al., "TLR2 deficiency by compromising p19 (IL-23) expression limits Th17 cell responses to mycobacterium tuberculosis," International Immunology, vol. 23, no. 2, pp. 89-96, 2011.

[10] C. X. Lima, D. G. Souza, F. A. Amaral et al., "Therapeutic effects of treatment with anti-TLR2 and anti-TLR4 monoclonal antibodies in polymicrobial sepsis," PLoS One, vol. 10, no. 7, article e0132336, 2015.

[11] J. Gao, Z. Jiang, S. Wang, Y. Zhou, X. Shi, and M. Feng, "Endoplasmic reticulum stress of Kupffer cells involved in the conversion of natural regulatory T cells to Th17 cells in liver ischemia-reperfusion injury," Journal of Gastroenterology and Hepatology, vol. 31, no. 4, pp. 883-889, 2016.

[12] A. Shimamoto, A. J. Chong, M. Yada et al., "Inhibition of Toll-like receptor 4 with eritoran attenuates myocardial ischemia-reperfusion injury," Circulation, vol. 114, no. 1, pp. I270-I274, 2006.

[13] S. B. Anderberg, T. Luther, and R. Frithiof, "Physiological aspects of Toll-like receptor 4 activation in sepsis-induced acute kidney injury," Acta Physiologica, vol. 219, no. 3, pp. 573-588, 2016.

[14] M. S. Duthie, H. P. Windish, C. B. Fox, and S. G. Reed, "Use of defined TLR ligands as adjuvants within human vaccines," Immunological Reviews, vol. 239, no. 1, pp. 178-196, 2011.

[15] G. Trinchieri and A. Sher, "Cooperation of Toll-like receptor signals in innate immune defense," Nature Reviews Immunology, vol. 7, no. 3, pp. 179-190, 2007.

[16] R. Anuradha, K. Chakraborty, and P. Ray, "Immunosuppressive MDSCs induced by TLR signaling during infection and role in resolution of inflammation," Frontiers in Cellular and Infection Microbiology, vol. 3, p. 52, 2013.

[17] M. A. Dobrovolskaia, A. E. Medvedev, K. E. Thomas et al., "Induction of in vitro reprogramming by toll-like receptor (TLR)2 and TLR4 agonists in murine macrophages: effects of TLR "homotolerance" versus "heterotolerance" on NF-[kappa]B signaling pathway components," The Journal of Immunology, vol. 170, no. 1, pp. 508-519, 2003.

[18] M. I. Arshad, S. Patrat-Delon, C. Piquet-Pellorce et al., "Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis," PLoS One, vol. 8, no. 9, article e74278, 2013.

[19] N. Kuroda, K. Inoue, T. Ikeda, Y. Hara, K. Wake, and T. Sato, "Apoptotic response through a high mobility box 1 protein-dependent mechanism in LPS/GalN-induced mouse liver failure and glycyrrhizin-mediated inhibition," PLoS One, vol. 9, no. 4, article e92884, 2014.

[20] Charles river, "Control data of each strain," 2017, http://www .crj.co.jp/cms/pdf/info_common/17/6033572/Contro_data_ 6_April_2011ca.pdf. http://www.crj.co.jp/cms/pdf/info_ common/C3H-IGS_CRLJ_nov_2013.pdf.

[21] M. E. Bianch, "DAMPs, PAMPs and alarmins: all we need to know about danger," Journal of Leukocyte Biology, vol. 81, no. 1, pp. 1-5, 2007.

[22] R. Jacinto, T. Hartung, C. McCall, and L. Li, "Lipopolysaccharide- and lipoteichoic acid-induced tolerance and crosstolerance: distinct alterations in IL-1 receptor-associated kinase," The Journal of Immunology, vol. 168, no. 12, pp. 6136-6141, 2002.

[23] S. Sato, F. Nomura, T. Kawai et al., "Synergy and cross-tolerance between toll-like receptor (TLR) 2- and TLR4mediated signaling pathways," The Journal of Immunology, vol. 165, no. 12, pp. 7096-7101, 2000.

[24] S. Furuya, H. Kono, M. Hara, K. Hirayama, C. Sun, and H. Fujii, "Interleukin 17A plays a role in lipopolysaccharide/D-galactosamine-induced fulminant hepatic injury in mice," Journal of Surgical Research, vol. 199, no. 2, pp. 487-493, 2015.

[25] J. D. Turner, R. S. Langley, K. L. Johnston et al., "Wolbachia endosymbiotic bacteria of Brugia malayi mediate macrophage tolerance to TLR- and CD40-specific stimuli in a MyD88/TLR2-dependent manner," The Journal of Immunology, vol. 177, no. 2, pp. 1240-1249, 2006.

[26] S. Manicassamy, R. Ravindran, J. Deng et al., "Toll-like receptor 2-dependent induction of vitamin A-metabolizing enzymes in dendritic cells promotes T regulatory responses and inhibits autoimmunity," Nature Medicine, vol. 15, no. 4, pp. 401-409, 2009.

[27] T. Kondo, T. Kawai, and S. Akira, "Dissecting negative regulation of Toll-like receptor signaling," Trends in Immunology, vol. 33, no. 9, pp. 449-458, 2012.

[28] K. Nakayama, S. Okugawa, S. Yanagimoto et al., "Involvement of IRAK-M in peptidoglycan-induced tolerance in macrophages," Journal of Biological Chemistry, vol. 279, no. 8, pp. 6629-6634, 2004.

[29] Y. Xiong, M. Pennini, S. N. Vogel, and A. E. Medvedev, "IRAK4 kinase activity is not required for induction of endotoxin tolerance but contributes to TLR2-mediated tolerance," Journal of Leukocyto Biology, vol. 94, no. 2, pp. 291-300, 2013.

[30] R. Nakagawa, T. Naka, H. Tsutsui et al., "SOCS-1 participates in negative regulation of LPS responses," Immunity, vol. 17, no. 5, pp. 677-687, 2002.

[31] A. Mansell, R. Smith, S. L. Doyle et al., "Suppressor of cytokine signaling 1 negatively regulates Toll-like receptor signaling by mediating Mal degradation," Nature Immunology, vol. 7, no. 2, pp. 148-155, 2006.

[32] J. M. Otte, E. Cario, and D. K. Podolsky, "Mechanisms of cross hyporesponsiveness to Toll-like receptor bacterial ligands in intestinal epithelial cells," Gastroenterology, vol. 126, no. 4, pp. 1054-1070, 2004.

[33] D. L. Boone, E. E. Turer, E. G. Lee et al., "The ubiquitin-modifying enzyme A20 is required for termination of Tolllike receptor responses," Nature Immunology, vol. 5, no. 10, pp. 1052-1060, 2004.

[34] O. Ananieva, J. Darragh, C. Johansen et al., "The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling," Nature Immunology, vol. 9, no. 9, pp. 1028-1036, 2008.

[35] S. Mukhopadhyay, A. Pluddemann, J. C. Hoe et al., "Immune inhibitory ligand CD200 induction by TLRs and NLRs limits macrophage activation to protect the host from meningococcal septicemia," Cell Host & Microbe, vol. 8, no. 3, pp. 236-247, 2010.

[36] P. E. Almeida, A. R. Silva, C. M. Maya-Monteiro et al., "Mycobacterium bovis Bacillus Calmette-Guerin infection induces TLR2-dependent peroxisome proliferator-activated receptor Y expression and activation: functions in inflammation, lipid metabolism, and pathogenesis," The Journal of Immunology, vol. 183, no. 2, pp. 1337-1345, 2009.

[37] R. Seki and K. Nishizawa, "Factors regulating Th17 cells: a review," Biomedical Research and Clinical Practice, vol. 1, no. 4, pp. 126-147, 2016.

[38] M. A. Nahid, K. M. Pauley, M. Satoh, and E. K. Chan, "miR-146a is critical for endotoxin-induced tolerance: IMPLICATION IN INNATE IMMUNITY," The Journal of Biological Chemistry, vol. 284, no. 50, pp. 34590-34599, 2009.

[39] E. M. Quinn, J. H. Wang, G. O'Callaghan, and H. P. Redmond, "MicroRNA-146a is upregulated by and negatively regulates TLR2 signaling," PLoS One, vol. 8, no. 4, article e62232, 2013.

[40] R. M. O'Connell, K. D. Taganov, M. P. Boldin, G. Cheng, and D. Baltimore, "MicroRNA-155 is induced during the macrophage inflammatory response," Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 5, pp. 1604-1609, 2007.

[41] Y. Li and X. Shi, "MicroRNAs in the regulation of TLR and RIG-I pathways," Cellular and Molecular Immunology, vol. 10, no. 1, pp. 65-71, 2013.

[42] M. A. Nahid, B. Yao, P. R. Dominguez-Gutierrez, L. Kesavalu, M. Satoh, and E. K. Chan, "Regulation of TLR2-mediated tolerance and cross-tolerance through IRAK4 modulation by miR-132 and miR-212," The Journal of Immunology, vol. 190, no. 3, pp. 250-1263, 2013.

[43] A. Boonstra, R. Rajsbaum, M. Holman et al., "Macrophages and myeloid dendritic cells, but not plasmacytoid dendritic cells, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals," The Journal of Immunology, vol. 177, no. 11, pp. 7551-7558, 2006.

[44] J. Lee, J. H. Mo, K. Katakura et al., "Maintenance of colonic homeostasis by distinctive apical TLR9 signaling in intestinal epithelial cells," Nature Cell Biology, vol. 8, no. 12, pp. 1327-1336, 2006.

[45] A. H. Dalpke, M. D. Lehner, T. Hartung, and K. Heeg, "Differential effects of CpG-DNA in toll-like receptor-2/-4/-9 tolerance and cross-tolerance," Immunology, vol. 116, no. 2, pp. 203-212, 2005.

[46] T. Liu, T. Matsuguchi, N. Tsuboiet, T. Yajima, and Y. Yoshikai, "Differences in expression of Toll-like receptors and their reactivities in dendritic cells in BALB/c and C57BL/6 mice," Infection and Immunity, vol. 7, no. 12, pp. 6638-6645, 2002.

[47] D. Stewart, W. B. Fulton, C. Wilson et al., "Genetic contribution to the septic response in a mouse model," Shock, vol. 18, no. 4, pp. 342-347, 2002.

[48] C. S. Hsieh, S. E. Macatonia, A. O'Garra, and K. M. Murphy, "T cell genetic background determines default T helper phenotype development in vitro," The Journal of Experimental Medicine, vol. 181, no. 2, pp. 713-721, 1995.

[49] C. D. Mills, K. Kincaid, J. M. Alt, M. J. Heilman, and A. M. Hill, "M-1/M-2 macrophages and the Th1/Th2 paradigm," The Journal of Immunology, vol. 164, no. 12, pp. 6166-6173, 2000.

[50] E. Kuroda and U. Yamashita, "Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice," The Journal of Immunology, vol. 170, no. 2, pp. 757-764, 2003.

[51] E. Kuroda, T. Kito, and U. Yamashita, "Reduced expression of STAT4 and IFN-y in macrophages from BALB/c mice," The Journal of Immunology, vol. 168, no. 11, pp. 5477-5482, 2002.

[52] H. Watanabe, K. Numata, T. Ito, K. Takagi, and A. Matsukawa, "Innate immune response in Th1- and Th2-dominant mouse strains," Shock, vol. 22, no. 5, pp. 460-466, 2004.

Reiko Seki

Teikyo University School of Medical Technology, Itabashi, Tokyo, Japan

Correspondence should be addressed to Reiko Seki; hyk@med.teikyo-u.ac.jp

Received 28 March 2017; Revised 10 August 2017; Accepted 13 September 2017; Published 17 October 2017

Academic Editor: Xiao-Feng Yang

Caption: Figure 1: Effect of CpG/D-galN in TLR4(+) and (-) mice. (a) Histological analysis of the liver with hematoxylin-eosin staining. Scale bars indicate 100 [micro]m. (b) Serum ALT levels. ** p < 0.05; *** p < 0.03.

Caption: Figure 2: Survival rate analysis of the tolerance-inducing effect of LTA pretreatment based on the Kaplan-Meier method. (a) C57BL/6J mice treated with CpG/D-galN. (b) C57BL/6J mice treated with R848/D-galN. (c) C3H mice treated with R848/D-galN.
Table 1: Serum ALT levels in each TLRL-D-galN-treated mouse. Mean
[+ or -] SD is shown.

Treatment (per mouse)                   n       Serum ALT levels
                                                    (U/1) (1)

                                                    C57BL/6J

PBS                                     5      79.8 [+ or -] 11.4
D-galN 20 mg                            5      71.0 [+ or -] 24.6
LPS 1 [micro]g                          4      100.0 [+ or -] 16.4
LPS 0.01 [micro]g/D-galN 20mg           5     280.3 [+ or -] 163.5
LPS 0.1 [micro]g/D-galN 20 mg           3    4830.0 [+ or -] 1429.0
                                                 (died at 5-6h)
LPS 1 [micro]g/D-galN 20 mg             3    3193.3 [+ or -] 1885.0
                                                  (died at 5-6h)
LTA 100 [micro]g                        4      83.8 [+ or -] 55.1
LTA 50 [micro]g/D-galN 20 mg            5     544.2 [+ or -] 162.1
LTA 100 [micro]g/D-galN 20mg            5    2780.0 [+ or -] 1128.6
R848 10 [micro]g                        4      90.3 [+ or -] 37.6
R848 1 [micro]g/D-galN 20 mg            5      165.4 [+ or -] 64.9
R848 10 [micro]g/D-galN 20 mg           5    9307.0 [+ or -] 5112.5
                                                 (died at 6-9 h)
poly (I:C) 5 [micro]g                   4      77.4 [+ or -] 20.5
poly (I:C) 2.5 [micro]g/D-galN 20 mg    5    15005.0 [+ or -] 1653.1
poly (I:C) 5 [micro]g/D-galN 20 mg      5    6486.0 [+ or -] 5779.0
                                                (died at 5-10 h)
CpGDNA 10 [micro]g                      4      76.5 [+ or -] 24.4
CpG DNA 10 [micro]g/D-galN 20 mg        5      90.4 [+ or -] 22.9
CpG DNA 20 [micro]g/D-galN 20 mg        5   10021.7 [+ or -] 3927.3
                                                 (died at 9-10h)

Treatment (per mouse)                         Serum ALT levels
                                                  (U/1) (1)

                                                     C3H

PBS                                           45.8 [+ or -] 12.3
D-galN 20 mg                                  66.4 [+ or -] 25.2
LPS 1 [micro]g                                96.3 [+ or -] 48.1
LPS 0.01 [micro]g/D-galN 20mg                114.3 [+ or -] 38.8
LPS 0.1 [micro]g/D-galN 20 mg              14713.3 [+ or -] 3131.5

LPS 1 [micro]g/D-galN 20 mg                13335.0 [+ or -] 5877.2
                                               (died at 6-9 h)
LTA 100 [micro]g                              54.0 [+ or -] 36.8
LTA 50 [micro]g/D-galN 20 mg                  91.8 [+ or -] 51.8
LTA 100 [micro]g/D-galN 20mg                 126.8 [+ or -] 52.6
R848 10 [micro]g                              51.8 [+ or -] 4.4
R848 1 [micro]g/D-galN 20 mg                1301.2 [+ or -] 1031.7
R848 10 [micro]g/D-galN 20 mg              6622.0 [+ or -] 2851.1
                                                (died at 7-9h)
poly (I:C) 5 [micro]g                         63.0 [+ or -] 27.2
poly (I:C) 2.5 [micro]g/D-galN 20 mg         307.6 [+ or -] 254.7
poly (I:C) 5 [micro]g/D-galN 20 mg           270.6 [+ or -] 249.5

CpGDNA 10 [micro]g                            41.7 [+ or -] 17.4
CpG DNA 10 [micro]g/D-galN 20 mg              70.8 [+ or -] 16.9
CpG DNA 20 [micro]g/D-galN 20 mg             318.8 [+ or -] 163.6

(1) The reference range (mean [+ or -] SD) of ALT has been reported
to be 27.7 [+ or -] 3.09 and 25.6 [+ or -] 12.0 for C57BL/6 and C3H,
respectively [20].

Table 2: Effect of CpG (20 [micro]g), R848 (10 [micro]g), and LTA
(100 [micro]g) in D-galN-(20 mg-mouse) sensitized mice. Mean
[+ or -] SD is shown.

                             Survival                 ALT (U/l)
PBS (n = 5)
  C57BL/6              All survived by 10 h      63.5 [+ or -] 14.5
  C3H                  All survived by 10 h      52.3 [+ or -] 10.8
CpG/D-galN (n = 8)
  C57BL/6              Four of eight died      18330.0 [+ or -] 5482.9
                           within 10 h
  C3H                  Four of eight died       267.7 [+ or -] 173.5
                           within 10 h
R848/D-galN (n = 8)
  C57BL/6                All eight died        12675.7 [+ or -] 6365.7
                            within 9 h
  C3H                    All eight died        5071.2 [+ or -] 2417.6
                            within 9 h
LTA/D-galN (n = 3)
  C57BL/6              All survived by 10 h    2536.7 [+ or -] 1346.0
  C3H                  All survived by 10 h      103.3 [+ or -] 35.6

                      TNF-[alpha] (pg/ml)         IL-6 (pg/ml)
PBS (n = 5)
  C57BL/6               3.2 [+ or -] 0.5        5.2 [+ or -] 1.8
  C3H                   2.1 [+ or -] 0.3        4.3 [+ or -] 2.8
CpG/D-galN (n = 8)
  C57BL/6             644.3 [+ or -] 187.7   1984.7 [+ or -] 771.4
  C3H                  31.5 [+ or -] 43.6     105.2 [+ or -] 100.4

R848/D-galN (n = 8)
  C57BL/6             337.6 [+ or -] 140.3   1029.4 [+ or -] 927.3
  C3H                 686.0 [+ or -] 406.7   1657.0 [+ or -] 813.2

LTA/D-galN (n = 3)
  C57BL/6              63.0 [+ or -] 18.0    3208.0 [+ or -] 1046.3
  C3H                   8.2 [+ or -] 7.0      626.2 [+ or -] 290.9

Table 3: Serum levels of cytokines (pg-ml) in a set of experiments
with C57BL-6 mice. Mean [+ or -] SD is shown.

Cytokine      Time         PBS          CpG/D-galN ([dagger])
                         (n = 7)
                                              LTA- (n = 7)

ALT (U/l)            68 [+ or -] 13     17875.7 [+ or -] 5156.2
                          (10h)                (7.5-10 h)

TNF-[alpha]    5h    1.5 [+ or -] 0.3      22.7 [+ or -] 21.0
              10h          n.t.            39.8 [+ or -] 13.0
IL-6           1h    2.4 [+ or -] 1.6    1984.7 [+ or -] 771.4
               5h    2.1 [+ or -] 0.8    1270.5 [+ or -] 1199.0
              10 h         n.t.         4424.81 [+ or -] 3718.7
INF-[gamma]    1h    1.4 [+ or -] 0.6       1.3 [+ or -] 0.5
               5h    1.3 [+ or -] 0.7      89.5 [+ or -] 74.6
              10h          n.t.          128.51 [+ or -] 147.2
IL-10          1h          n.t.            23.7 [+ or -] 18.6
               5h          n.t.            90.2 [+ or -] 93.1
              10h          n.t.          270.01 [+ or -] 249.5
IL-17A         1h          n.t.             2.1 [+ or -] 1.1
               5h          n.t.             2.6 [+ or -] 2.1
              10h          n.t.            1.01 [+ or -] 0.6
IL-23          1h          n.t.            16.7 [+ or -] 3.4
               5h          n.t.            15.0 [+ or -] 4.6
              10h          n.t.            18.31 [+ or -] 8.3
IL-27          1h          n.t.             4.6 [+ or -] 2.5
               5h          n.t.             8.2 [+ or -] 4.6
              10h          n.t.            5.51 [+ or -] 3.0

Cytokine      Time     CpG/D-galN ([dagger])

                           LTA+ (n = 7)

ALT (U/l)            202.4 [+ or -] 108.2 ***
                              (10 h)

TNF-[alpha]    5h        7.3 [+ or -] 0.5
              10h      3.0 [+ or -] 0.0 ***
IL-6           1h     67.7 [+ or -] 29.7 ***
               5h       112.5 [+ or -] 51.4
              10 h    33.2 [+ or -] 24.8 ***
INF-[gamma]    1h       1.6 [+ or -] 1.2 *
               5h       13.7 [+ or -] 5.4 *
              10h      6.5 [+ or -] 4.8 ***
IL-10          1h       6.2 [+ or -] 8.3 *
               5h       63.2 [+ or -] 62.0
              10h      2.0 [+ or -] 0.0 ***
IL-17A         1h        2.4 [+ or -] 2.2
               5h        4.9 [+ or -] 3.5
              10h        1.0 [+ or -] 0.0
IL-23          1h      10.5 [+ or -] 3.7 **
               5h        16.5 [+ or -] 3.7
              10h       9.0 [+ or -] 0.0 *
IL-27          1h        7.5 [+ or -] 5.0
               5h        11.0 [+ or -] 8.2
              10h       2.4 [+ or -] 1.1 **

Cytokine      Time   R848/D-galN ([dagger])

                           LTA- (n = 7)

ALT (U/l)            14737.5 [+ or -] 3894.0
                            (6-8.5 h)

TNF-[alpha]    5h       15.5 [+ or -] 10.8
              10h     Not available (death)
IL-6           1h     1029.4 [+ or -] 927.3
               5h      297.7 [+ or -] 210.9
              10 h    Not available (death)
INF-[gamma]    1h        1.1 [+ or -] 0.6
               5h       52.8 [+ or -] 33.1
              10h     Not available (death)
IL-10          1h        6.9 [+ or -] 4.3
               5h       26.6 [+ or -] 10.8
              10h     Not available (death)
IL-17A         1h       1.75 [+ or -] 1.0
               5h        1.1 [+ or -] 0.8
              10h     Not available (death)
IL-23          1h       12.4 [+ or -] 4.7
               5h        9.4 [+ or -] 3.8
              10h     Not available (death)
IL-27          1h        2.6 [+ or -] 1.4
               5h        3.1 [+ or -] 1.5
              10h     Not available (death)

Cytokine      Time    R848/D-galN ([dagger])

                           LTA+ (n = 7)

ALT (U/l)            10112.1 [+ or -] 5229.2
                             (8-10h)

TNF-[alpha]    5h        9.6 [+ or -] 3.4
              10h              n.t.
IL-6           1h      668.6 [+ or -] 481.5
               5h      359.4 [+ or -] 294.2
              10 h             n.t.
INF-[gamma]    1h        1.5 [+ or -] 0.5
               5h       54.0 [+ or -] 9.4
              10h              n.t.
IL-10          1h        2.7 [+ or -] 1.7
               5h      6.4 [+ or -] 4.7 ***
              10h              n.t.
IL-17A         1h        2.0 [+ or -] 1.3
               5h      2.7 [+ or -] 0.8 ***
              10h              n.t.
IL-23          1h       14.3 [+ or -] 7.4
               5h     16.7 [+ or -] 3.4 ***
              10h              n.t.
IL-27          1h        4.7 [+ or -] 2.6
               5h     10.3 [+ or -] 5.6 ***
              10h              n.t.

n.t.: not tested. ([dagger]) PBS (LTA-mice) or 200 [micro]g-mouse LTA
(LTA+ mice) was administered 24 h prior to the challenge with the 20
[micro]g CpG (or 10 [micro]g R848)-20 [micro]g D-galN. Asterisks
indicate a significant difference between with and without the LTA
pretreatment (* p < 0.05, ** p < 0.03, and *** p < 0.01). (1) Two out
of seven mice died within 10 h, and the five mice that survived
within 10 h were analyzed.
COPYRIGHT 2017 Hindawi Limited
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research Article
Author:Seki, Reiko
Publication:Journal of Immunology Research
Date:Jan 1, 2017
Words:7939
Previous Article:TNF Tolerance in Monocytes and Macrophages: Characteristics and Molecular Mechanisms.
Next Article:Neutrophils and Immunity: From Bactericidal Action to Being Conquered.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters